Making therapies that make a difference

Our clinical and preclinical pipeline includes wholly-owned and partnered therapeutic candidates initially targeting cancers.

Pipeline of Potential

Lead Product Candidates

Preclinical
Phase 1
Phase 2
Pivotal
Commercial Rights

Zanidatamab

HER2 x HER2 Bispecific Antibody

  • Azymetric™
Pivotal
BeiGene rights in Asia Pacific countries including China, South Korea, Australia, and New Zealand but excluding Japan.
  • Biliary Tract Cancers
  • Breast Cancer
  • Gastroesophageal Adenocarcinomas
  • Colorectal Cancer
  • HER2-Expressing Cancers
Full Details
  • 1st-Line Gastroesophageal Adenocarcinomas (HERIZON-GEA-01)
  • Pivotal

    Chemotherapy Combination

    Now Enrolling Patients
  • 2nd-Line Biliary Tract Cancers (HERIZON-BTC-01)
  • Pivotal

    Monotherapy

    FDA Breakthrough Therapy Designation

    Enrollment Complete
  • 1st-Line Gastrointestinal Cancers (Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer)
  • Phase 2

    Chemotherapy Combination

    Now Enrolling Patients
  • Late-Line Breast Cancer
  • Phase 2

    Combination with Palbociclib & Fulvestrant

    Now Enrolling Patients
  • HER2-Expressing Cancers
  • Phase 1

    Monotherapy & Chemotherapy Combination

    Now Enrolling Patients

    Zanidatamab Zovodotin

    HER2 x HER2 Bispecific Antibody Drug Conjugate (ADC)

    • Azymetric™
    • ZymeLink™
    Phase 1
    BeiGene rights in Asia Pacific countries including China, South Korea, Australia, and New Zealand but excluding Japan.
    • HER2-Expressing Cancers
    Full Details
  • HER2-Expressing Cancers
  • Phase 1

    Preclinical & Advanced Discovery

    Preclinical
    Phase 1
    Phase 2
    Pivotal
    Commercial Rights

    ZW191 - TOPO1i Antibody Drug Conjugate (ADC)

    TOPO1i Antibody Drug Conjugate (ADC)

    • ZymeLink™
    Preclinical
    • Ovarian Cancer & Gynecological Cancers
    Full Details

    ZW171 - 2+1 T-Cell Engaging Bispecific

    • Azymetric™
    Preclinical
    • Solid Tumors
    Full Details

    Partnerships

    Preclinical
    Phase 1
    Phase 2
    Pivotal
    Commercial Rights

    Bispecific

    • Azymetric™
    • EFECT™
    Phase 1
    We entered into a collaboration with Celgene (which is now a Bristol-Myers Squibb company)
    • Oncology
    Full Details

    XB002 Tissue Factor ADC

    • ZymeLink™
    Phase 1
    Original Agreement with Iconic; XB002 in-licensed by Exelixis
    • Solid Tumors
    Full Details

    JNJ-78278343 (CD3 x KLK2)

    • Azymetric™
    • EFECT™
    Phase 1
    • Castration-Resistant Prostate Cancer
    Full Details

    JNJ-78306358 (CD3 X HLA-G)

    • Azymetric™
    • EFECT™
    Phase 1
    • Solid Tumors
    Full Details

    Bispecific

    • Azymetric™
    • EFECT™
    Preclinical
    • Undisclosed
    Full Details

    Bispecific

    • Azymetric™
    • EFECT™
    Preclinical
    • Immuno-Oncology
    Full Details

    Bispecific

    • Azymetric™
    Preclinical
    • Infectious Disease
    Full Details

    Undisclosed

    • EFECT™
    Preclinical
    • Undisclosed
    Full Details

    Bispecific

    • Azymetric™
    • EFECT™
    Preclinical
    • Dermatology
    Full Details

    ATRC-301 (EphA2 ADC)

    • ZymeLink™
    Preclinical
    Full Details

    2022-12-06 19:17